SGMT — Sagimet Biosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1400118 ·
Last close
$8.92
Market Cap
$549.39M
52W High
$11.45
52W Low
$4.50
ADV30
1,291,088
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -15,818,000 | -13,953,000 | 263,430,000 | 165,896,000 | 7,275,000 |
| Mar 2026 | 0 | — | -11,713,000 | -10,650,000 | 107,755,000 | 36,626,000 | 5,297,000 |
| Dec 2025 | 0 | — | -10,765,000 | -9,568,000 | 116,482,000 | 35,021,000 | 5,101,000 |
| Sep 2025 | 0 | — | -14,334,000 | -12,908,000 | 128,401,000 | 32,496,000 | 9,146,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,725,000
Investing CF
$11,359,000
Financing CF
$275,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-356,999,000
Inventory
—
Receivables
—
ST Investments
$67,913,000
EBIT TTM
$-48,737,000
Pretax Income TTM
$-43,512,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,889,000 | -51,038,000 | 116,482,000 | 5,101,000 | 111,381,000 | -45,650,000 |
| Dec 2024 | 0 | -54,454,000 | -45,567,000 | 160,259,000 | 4,454,000 | 155,805,000 | -42,435,000 |
| Dec 2023 | 2,000,000 | -30,740,000 | -27,876,000 | 96,719,000 | 5,654,000 | 91,065,000 | -23,766,000 |
| Dec 2022 | 0 | -31,055,000 | -30,499,000 | 33,031,000 | 219,981,000 | -186,950,000 | -24,490,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-43,512,000
OpCashFlow TTM
—
Assets (Latest)
$107,755,000
Forward EPS
$-1.37
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $8.92 · call oi: 7,689 · put oi: 4,911
Expected Move to 2026-10-16:
±$1.50
(16.82%) —
implied range
$7.42 –
$10.42
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $557.88M | $3.79 | — |
| EVO | Evotec SE | $557.96M | $1.57 | — |
| CTMX | CytomX Therapeutics, Inc. | $538.21M | $2.47 | — |
| BLSM | BlossomHill Therapeutics, Inc. | $536.53M | $16.88 | — |
| MNPR | Monopar Therapeutics | $563.69M | $83.98 | — |
News headlines (Yahoo Finance, 1h cache)
Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
2026-10-09 12:18 · Yahoo
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermat
2026-10-09 11:00 · Yahoo
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
2026-10-04 01:02 · Yahoo
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
2026-10-01 20:31 · Yahoo
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data
2026-09-30 13:52 · Yahoo
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market
2026-09-30 12:17 · Yahoo
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
2026-09-30 10:59 · Yahoo
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
2026-09-30 10:19 · Yahoo
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
2026-09-30 10:00 · Yahoo
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
2026-09-28 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.